|
2024
|
Invention
|
Arylamine compound having protein degradation effect. Provided in the present disclosure is a new... |
|
|
Invention
|
Compounds having ptpn2 inhibitory effects and use thereof. Disclosed are compounds having PTPN2 i... |
|
|
Invention
|
Glp1r agonist and preparation method for intermediate thereof. A GLP1R agonist and a preparation ... |
|
|
Invention
|
Cordyceps sinensis fermentation composition. A cordyceps sinensis fermentation composition, conta... |
|
|
Invention
|
Cordyceps sinensis fermentation composition. A Cordyceps sinensis fermentation composition, compr... |
|
|
Invention
|
Novel anti-fgfr2 antibodies. Provided are an anti-FGFR2b antibody or antigen-binding fragments th... |
|
|
Invention
|
Externally applied composition of minoxidil and ruxolitinib, and use thereof. Disclosed in the pr... |
|
|
Invention
|
Glp-1 receptor agonist and composition and use thereof.
Provided are a GLP-1 receptor agonist co... |
|
|
Invention
|
Glp-1/gip dual agonist, preparation method and use thereof.
The present invention relates to lon... |
|
|
Invention
|
Gip receptor agonist and use thereof.
The present invention is in the field of biomedical techno... |
|
|
Invention
|
Gip receptor agonist and use thereof. Disclosed are a peptide compound having an agonistic activi... |
|
|
Invention
|
Gip receptor agonist and use thereof. The present invention is in the field of biomedical technol... |
|
2023
|
Invention
|
Oxime-containing compound having sting inhibitory effect, pharmaceutical composition thereof, and... |
|
|
Invention
|
Kras-protac chimeric compound, preparation method therefor and use thereof. The present invention... |
|
|
Invention
|
Protac chimeric compound, preparation method therefor and use thereof. A compound represented by ... |
|
|
Invention
|
Novel crystal form of glp-1 receptor agonist, method for preparing same, pharmaceutical compositi... |
|
|
Invention
|
Salt-type glp-1 receptor agonist, crystal form thereof, preparation method therefor, pharmaceutic... |
|
|
Invention
|
Antibody targeting cd112r or antigen-binding fragment thereof and use thereof. The present applic... |
|
|
Invention
|
1,5-naphthyridine cgas inhibitor and use thereof. 00) and a pharmaceutically acceptable salt ther... |
|
|
Invention
|
Glp-1 receptor agonist and composition and use thereof. Provided are a GLP-1 receptor agonist com... |
|
|
Invention
|
Amide compound having sting inhibitory effect, and pharmaceutical composition and use thereof. A ... |
|
|
Invention
|
Compound having kras g12d inhibitory effect. Disclosed are a compound as represented by formula (... |
|
|
Invention
|
Protac chimeric compound, preparation method therefor and use thereof. Disclosed are a chimeric c... |
|
|
Invention
|
Glp-1/gip dual agonist, and preparation method therefor and use thereof. A long-acting GLP-1/GIP ... |
|
|
Invention
|
Novel anti-fgfr2 antibodies. Disclosed are anti-FGFR2b antibody or antigen-binding fragments ther... |
|
|
Invention
|
Ror1-targeted binding molecule and use thereof. The present application relates to an antibody sp... |
|
|
Invention
|
Ror1-targeted antibody or antigen-binding fragment thereof and use thereof. The present applicati... |
|
|
Invention
|
Pyrrole fused-ring pyrazole compound, and preparation method therefor and use thereof. The presen... |
|
2022
|
Invention
|
Method for improving biological fermentation level of acarbose. A method for improving the biolog... |
|
|
Invention
|
Crystal form of salt of pyrazine derivative, and preparation method therefor. 3,6-diamino-2,5-bis... |
|
|
Invention
|
Ruxolitinib composition and preparation method therefor.
Disclosed in the present invention is a... |
|
|
Invention
|
Ruxolitinib composition and preparation method therefor. Disclosed in the present invention is a ... |
|
|
Invention
|
Ruxolitinib composition and use thereof. The present invention relates to a composition of ruxoli... |
|
|
Invention
|
Ansamitocin p-3 fermentation method. An Ansamitocin fermentation method, comprising fermentation ... |
|
|
Invention
|
Solid composition of glp-1 receptor agonist. Provided in the present invention is a pharmaceutica... |
|
|
Invention
|
Hydrogenation synthesis method for preparing pyrazinecarboxylic acid derivative as fluorescent tr... |
|
|
Invention
|
Method for preparing pneumocandin b0 by fermentation. A method for the stable and efficient produ... |
|
|
Invention
|
Crystal form of pyrazine derivative and preparation method therefor. A crystal form of a pyrazine... |
|
|
Invention
|
Camptothecin derivative intermediate and synthesis method therefor, and method for synthesizing c... |
|
|
Invention
|
Method for preparing glp-1 receptor agonist intermediate. Provided is a method for preparing (S,Z... |
|
|
Invention
|
Method for preparing pyrazine carboxylic acid derivative as fluorescent tracer. The present appli... |
|
|
Invention
|
Pretreatment process for acarbose fermentation liquid. The present invention belongs to the field... |
|
|
Invention
|
Method for preparing dehydrodidemnin b compound. A method for preparing a dehydrodidemnin B compo... |
|
|
Invention
|
Thiophene glp-1 receptor agonist and use thereof.
Provided are a series of thiophene GLP-I recep... |
|
2021
|
Invention
|
Fermentation method for mupirocin.
A fermentation method for mupirocin, the method comprising pe... |
|
|
Invention
|
Method for preparing 3,6-diaminopyrazine-2,5-dicarboxylic acid and synthetic intermediate thereof... |
|
|
Invention
|
Method for extracting mupirocin.
A method for extracting mupirocin. The main steps thereof compr... |
|
2020
|
Invention
|
Compound having khk inhibitory effect.
A compound having a KHK inhibitory effect, or pharmaceuti... |
